– IRELAND, Dublin – Amarin Corporation plc (NASDAQ: AMRN) today announced the appointments of Erin Enright and Chito Zulueta to its Board as Independent Directors, effective immediately.
The company also announced the nomination of Per Wold-Olsen, a director since January 2022, as Chairman of the Board of Directors, effective immediately, and the planned retirements of David Stack and Joe Zakrzewski from the Board, effective at the close of the 2022 AGM.
About Erin Enright
Ms. Enright brings more than 30 years of experience as a healthcare company executive and investor. She currently serves as Managing Partner at Prettybrook Partners, overseeing approximately 20 active investments in a variety of healthcare companies. Prior to her role at Prettybrook, Ms. Enright served as CFO of InfuSystem and as President of Lee Medical, a medical device manufacturer, from 2004 to 2013. From 1993 to 2003, Ms. Enright was with Citigroup, where she was Managing Director in its Equity Capital Markets group. While at Citigroup, Ms. Enright was Chairperson of the firm’s Institutional Investors Committee, responsible for screening and approving the firm’s participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm’s underwritings. She began her career as an attorney with Wachtell, Lipton, Rosen & Katz.
Ms. Enright currently serves as Chairman of the Board of Dynatronics Corporation, a director of the Medical Facilities Corporation Board serving as Audit and Investment Committee Chair, a member of the Board and Chair of the Audit Committee of Brooklyn ImmunoTherapeutics (NASDAQ:BTX), and a director of Keystone Dental, a privately held company where she serves as Audit Committee Chair. She has previously served as a director at Biolase, Inc., Tigerlabs and Ceelite Corporation.
Ms. Enright received her A.B. degree from the School of Public and International Affairs at Princeton University and J.D. degree from the University of Chicago Law School.
About Alfonso “Chito” Zulueta
Mr. Zulueta has more than three decades of experience in global strategic and leadership roles within large pharma, specifically with Eli Lilly and Company. At Eli Lilly, he held key senior positions including VP of Global Marketing, head of the Company’s Asia Region, and most recently as President of International responsible for all geographies outside the United States and Canada.
Prior to Mr. Zulueta’s retirement in 2021, he spent over three decades at Eli Lilly and Company in various roles of increasing responsibility, including most recently as President, International from 2017 until his retirement. He was a corporate officer and member of Eli Lilly and Company’s executive committee.
Mr. Zulueta currently serves on the Board of CTS Corporation where he serves on the audit and nominating and governance committees and Syneos Health as well as Glooko and Calidi Biotherapeutics, both privately held companies. He previously served as a member of the board of the European Federation of Pharmaceutical Industries and Associations (EFPIA), and US-Japan Business Council.
He received his Bachelor of Arts from De La Salle University in the Philippines, and his MBA from Colgate Darden Graduate School of Business Administration at the University of Virginia.
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our global commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin, in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.
For more information : https://amarincorp.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
